Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15
Mouth Diseases 44 73
Abnormality of the Mouth 29
Mouth Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 44 D009059
NCIt 50 C27641 C3240
UMLS 73 C0026636

Summaries for Mouth Disease

MedlinePlus : 43 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and viral infectious disease, and has symptoms including tinnitus, snoring and coughing. An important gene associated with Mouth Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Triclosan and sodium fluoride have been mentioned in the context of this disorder. Affiliated tissues include tongue, salivary gland and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 34.0 HMGB1 IFNG IL10 IL17F IL6 SCARB2
2 viral infectious disease 30.8 IFNA1 IFNG IL10 IL6 IRF3 STAT1
3 meningitis 30.3 CRP IFNG IL10 IL6
4 influenza 30.2 IFNA1 IFNG IRF3 TLR3
5 nervous system disease 29.9 CRP IFNG IL10 IL6
6 graft-versus-host disease 29.9 IFNG IL10 IL6
7 rabies 29.9 IRF3 STAT1 TLR3
8 kawasaki disease 29.9 CRP IL10 IL6
9 acute pancreatitis 29.8 CRP IL10 IL6
10 measles 29.8 IFNA1 IFNG IL6 STAT1 TLR3
11 severe acute respiratory syndrome 29.8 CRP IFNA1 IFNG IRF3 STAT1
12 burning mouth syndrome 11.1
13 oral hairy leukoplakia 10.7
14 hemorrhagic fever 10.4 IFNG IL10 IL6
15 multicentric castleman disease 10.4 CRP IL10 IL6
16 castleman disease 10.4 CRP IL10 IL6
17 pyelitis 10.4 CRP IL6 TLR4
18 relapsing polychondritis 10.3 CRP IFNG IL6
19 central nervous system vasculitis 10.3 CRP IFNG IL6
20 coccidioidomycosis 10.3 IL10 STAT1 TLR4
21 cystic echinococcosis 10.3 IL10 IL6 TLR4
22 viral meningitis 10.3 CRP IFNG IL6
23 intermediate uveitis 10.3 IFNG IL10 IL6
24 eales disease 10.3 IFNG IL10 IL6
25 acute pyelonephritis 10.3 CRP IL10 IL6
26 variola major 10.3 IFNG TLR3 TLR4
27 hematopoietic stem cell transplantation 10.3 IFNG IL10 IL6
28 scrub typhus 10.3 CRP IL10 TLR4
29 plasmodium vivax malaria 10.3 IFNG IL10 IL6
30 perinatal necrotizing enterocolitis 10.3 CRP IL6 TLR4
31 bacterial sepsis 10.3 CRP IL10 TLR4
32 cold agglutinin disease 10.3 CRP IL6
33 lymph node disease 10.3 CRP IL10 IL6
34 cephalosporin allergy 10.3 IFNG IL10
35 bacterial pneumonia 10.3 CRP IL6 TLR4
36 prostatitis 10.3 IL10 IL6 VDR
37 mixed connective tissue disease 10.3 IFNG IL10 IL6
38 pericarditis 10.3 CRP IFNG IL6
39 extrapulmonary tuberculosis 10.3 IFNG IL10 VDR
40 reactive arthritis 10.3 CRP IFNG IL10
41 temporal arteritis 10.3 CRP IFNG IL6
42 pulmonary tuberculosis 10.3 IFNG IL10 VDR
43 tropical spastic paraparesis 10.3 IFNG IL10 IL6
44 lepromatous leprosy 10.3 IFNG IL10 VDR
45 autoimmune disease of musculoskeletal system 10.3 CRP IL10 IL6
46 bronchiolitis obliterans 10.3 IFNG IL10 IL6
47 spondyloarthropathy 10.3 IFNG IL10 IL6
48 parasitic protozoa infectious disease 10.3 IFNG IL10 IL6
49 rasmussen encephalitis 10.3 HMGB1 IFNG IL6
50 hemorrhagic fever with renal syndrome 10.3 CRP IL6 VTN

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


tinnitus, snoring, coughing, sore throat, vertigo/dizziness, equilibration disorder, halitosis, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.53 CRP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.53 IL10
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.53 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.53 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.53 TLR4
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.53 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.53 EIF4G1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.53 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.53 EIF4G1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.53 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.53 CRP EIF4G1 IL10 TLR4
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.53 CRP
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.53 EIF4G1

MGI Mouse Phenotypes related to Mouth Disease:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 ATG5 BECN1 CRP IFNG IL10 IL6
2 homeostasis/metabolism MP:0005376 10.37 ATG5 BECN1 CRP IFNG IL10 IL6
3 hematopoietic system MP:0005397 10.36 ATG5 BECN1 IFNG IL10 IL17F IL6
4 immune system MP:0005387 10.35 ATG5 BECN1 CRP IFNG IL10 IL17F
5 behavior/neurological MP:0005386 10.32 ATG5 BECN1 IFNG IL10 IL6 ITGAV
6 cellular MP:0005384 10.3 ATG5 BECN1 IFNG IL10 IL6 IRF3
7 growth/size/body region MP:0005378 10.3 ATG5 BECN1 IFNG IL10 IL17F IL6
8 digestive/alimentary MP:0005381 10.25 ATG5 IFNG IL10 IL17F IL6 ITGAV
9 endocrine/exocrine gland MP:0005379 10.24 ATG5 BECN1 IFNG IL10 IL6 ITGAV
10 mortality/aging MP:0010768 10.22 ATG5 BECN1 IFNG IL10 IL17F IL6
11 muscle MP:0005369 10.07 ATG5 IFNG IL10 IL6 ITGAV NOTCH1
12 integument MP:0010771 10.06 BECN1 IFNG IL10 IL6 NOTCH1 STAT1
13 nervous system MP:0003631 10.03 ATG5 BECN1 IFNG IL10 IL6 ITGAV
14 liver/biliary system MP:0005370 9.98 ATG5 IFNG IL10 IL6 NOTCH1 STAT1
15 neoplasm MP:0002006 9.97 BECN1 IFNG IL10 IL6 ITGAV NOTCH1
16 normal MP:0002873 9.81 ATG5 EIF4G1 IFNG IL10 IL17F NOTCH1
17 renal/urinary system MP:0005367 9.56 ATG5 IFNG IL6 ITGAV NOTCH1 SCARB2
18 respiratory system MP:0005388 9.23 ATG5 IFNG IL10 IL17F IL6 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 892)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triclosan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 3380-34-5 5564
2 sodium fluoride Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7681-49-4
3
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
4
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
5
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9004-61-9 53477741
6
Pilocarpine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 26787-78-0 33613
9
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
10
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
11
Levonorgestrel Approved, Investigational Phase 4 17489-40-6, 797-63-7 13109
12
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 564-25-0 54671203
13
Polyestradiol phosphate Approved Phase 4 28014-46-2
14
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
15
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
16
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
17 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
18
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
19
Hexetidine Approved, Investigational Phase 4 141-94-6
20
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
21
Aminocaproic Acid Approved, Investigational Phase 4,Phase 3 60-32-2 564
22
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
23
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 103-90-2 1983
24
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1400-61-9 11953884
25
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
27
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
29
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Not Applicable 67-73-2 6215
30
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2 113775-47-6 68602 5311068
31
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
32
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 53-03-2 5865
33
Calcium Carbonate Approved, Investigational Phase 4,Not Applicable 471-34-1
34
Acyclovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59277-89-3 2022
35
Docosanol Approved, Investigational Phase 4 30303-65-2, 661-19-8 12620
36
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
37
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 62-33-9, 60-00-4 6049
38
Pentetic acid Approved Phase 4,Phase 3,Not Applicable 67-43-6
39
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
40
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
41
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 10118-90-8 5281021
42
Azithromycin Approved Phase 4,Phase 2,Not Applicable 83905-01-5 55185 447043
43
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 85721-33-1 2764
44
Thymol Approved Phase 4,Not Applicable 89-83-8 6989
45
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
46
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7440-66-6
47
Methyl salicylate Approved, Vet_approved Phase 4,Not Applicable 119-36-8 4133
48
Cetylpyridinium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7773-52-6
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3

Interventional clinical trials:

(show top 50) (show all 2890)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyanoacrylate Adhesive (PeriAcryl®90 HV) in Periodontal Wound Healing Unknown status NCT02826109 Phase 4
2 Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers Unknown status NCT02670135 Phase 4 Triclosan Containing Toothpaste;Triclosan Free Toothpaste
3 The Treatment of Periodontal Diseases Unknown status NCT01318928 Phase 4 Metronidazol
4 Effect of Actonel on Periodontal Health of Postmenopausal Women Unknown status NCT00594334 Phase 4 Risedronate
5 Efficacy and Safety of a Commercially Available Injectable Hyaluronic Acid Dental Filler for Periodontal Pockets Unknown status NCT02391974 Phase 4
6 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
7 Antiplaque Effect of Essential Oils With and Without Alcochol on an in Situ Model of Oral Biofilm Growth Unknown status NCT02946801 Phase 4 Essential oils;Essential oils without alcohol;Sterile water
8 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
9 Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis Unknown status NCT02135952 Phase 4 MTZ+AMX
10 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
11 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
12 Study of Scaling and Root Planing With PerioWave Versus Scaling and Root Planing Alone in Chronic Periodontitis Unknown status NCT00297531 Phase 4
13 SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis Unknown status NCT00296881 Phase 4
14 Norplant and Irregular Bleeding/Spotting Unknown status NCT00064766 Phase 4 doxycycline
15 Efficacy of Three Antibiotic Protocols for Aggressive Periodontitis Treatment Unknown status NCT02839421 Phase 4 Scaling and Root Planing combined with moxifloxacin
16 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
17 Methodology Antiseptic Application, Influence on Oral Biofilm. Unknown status NCT02267239 Phase 4 essential oils, immersion;Chlorhexidine, immersion;essential oils, mouthwash;chlorhexidine, mouthwash
18 Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis Unknown status NCT02789436 Phase 4 L. reuteri Prodentis® lozenges
19 Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients Unknown status NCT02238288 Phase 4 Aminocaproic acid;lidocaine and epinephrine;Paracetamol
20 Pinhole Surgical Technique With And Without Use Of Buttons For Treatment Of Multiple Gingival Recessions: RCT Unknown status NCT02632968 Phase 4
21 Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study Unknown status NCT02626117 Phase 4
22 Platelet Rich Fibrin in the Treatment of Palatal Wounds Unknown status NCT02438046 Phase 4
23 Oral Hygiene Regimen in Patients on HCT Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
24 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
25 Efficacy of Different Chlorhexidine Concentrations Unknown status NCT02911766 Phase 4 Chlorhexidine 0.2% Mouthrinse;Chlorhexidine 0.12% mouthrinse;Chlorhexidine 0.06% mouthrinse
26 Adhesion of Connective Tissue Around Laser-treated Abutments for Dental Implants - Clinical Trial in Humans Unknown status NCT01954485 Phase 4
27 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
28 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
29 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
30 Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair Unknown status NCT02915042 Phase 4 Dexmedetomidine;Placebo
31 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
32 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
33 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
34 Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis) Unknown status NCT00467662 Phase 4 Acyclovir 5%;Docosanol 10%
35 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
36 Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
37 Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine Completed NCT03278132 Phase 4
38 Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines Completed NCT03274102 Phase 4
39 Regenerative Surgical Treatment of Peri-implantitis Completed NCT02500654 Phase 4
40 Melatonin as an Adjunctive Therapy for Chronic Periodontitis. Completed NCT03368430 Phase 4 Placebo
41 Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy. Completed NCT02487186 Phase 4 Doxicicline
42 EMD and/or Bone Substitute for the Treatment of Class II Furcations Completed NCT02474498 Phase 4 EMD
43 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
44 Conventional or Minimally Invasive Surgical Technique for the Treatment of Furcation Defects Using Enamel Matrix Derivative and Anorganic Bovine Bone - a Randomized Controlled Clinical Trial. Completed NCT02102360 Phase 4
45 Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel Completed NCT01591616 Phase 4 lidocaine and prilocaine
46 Photodynamic Therapy During Supportive Periodontal Therapy Completed NCT02666573 Phase 4
47 The Effects of Periodontal Therapy on Glycemic Control in Diabetic Patients Completed NCT03783845 Phase 4 amoxicillin and metronidazole
48 "Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects" Completed NCT03677297 Phase 4 Rosuvastatin
49 Aloe Vera and Chlorhexidine Against Traumatic Oral Ulcers Completed NCT03633292 Phase 4 Antiseptic clorhexidine gel (Lacer, Barcelona, Spain);Master formula of aloe vera gel 80%
50 Evaluation of Antimicrobial Photodynamic Therapy in Multiple Applications as a Coadjuvant in the Surgical Therapy of Access to Scaling Completed NCT03498404 Phase 4

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Genetic tests related to Mouth Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Mouth 29

Anatomical Context for Mouth Disease

MalaCards organs/tissues related to Mouth Disease:

41
Tongue, Salivary Gland, Testes, Kidney, B Cells, Lung, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

19
The Mouth

Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 1701)
# Title Authors Year
1
Short-term effects of meteorological factors and air pollution on childhood hand-foot-mouth disease in Guilin, China. ( 30056233 )
2019
2
Exploring spatiotemporal nonstationary effects of climate factors on hand, foot, and mouth disease using Bayesian Spatiotemporally Varying Coefficients (STVC) model in Sichuan, China. ( 30121533 )
2019
3
Molecular characterization of Coxsackievirus A16 strains isolated from children with severe hand, foot, and mouth disease in Yunnan, Southwest China, during 2009-2015. ( 30168582 )
2019
4
Assessing the spread of foot and mouth disease in mainland China by dynamical switching model. ( 30273575 )
2019
5
Serotyping of foot-and-mouth disease virus using oxford nanopore sequencing. ( 30393148 )
2019
6
Foot-and-mouth disease virus nonstructural protein 2B interacts with cyclophilin A, modulating virus replication. ( 29906248 )
2018
7
Foot and mouth disease vaccine strain selection: Current approaches and future perspectives. ( 29950121 )
2018
8
Use of ENABLAr adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. ( 29358056 )
2018
9
Development of a rapid test for detection of foot-and-mouth disease virus specific antibodies using gold nanoparticles. ( 29911152 )
2018
10
Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016. ( 29362406 )
2018
11
Clinical profile and virology analysis of hand, foot and mouth disease cases from North Kerala, India in 2015-2016: A tertiary care hospital-based cross-sectional study. ( 29620046 )
2018
12
A spatiotemporal mixed model to assess the influence of environmental and socioeconomic factors on the incidence of hand, foot and mouth disease. ( 29463224 )
2018
13
An assessment of a pediatric early warning system score in severe hand-foot-and-mouth disease children: To detect clinical deterioration in hospitalized children. ( 29953028 )
2018
14
A partial deletion within foot-and-mouth disease virus non-structural protein 3A causes clinical attenuation in cattle but does not prevent subclinical infection. ( 29346074 )
2018
15
Cytokine and Chemokine Profiling in Patients with Hand, Foot and Mouth Disease in Singapore and Malaysia. ( 29511232 )
2018
16
Classical Hand, Foot and Mouth Disease Replaced by Atypical Hand, Foot and Mouth Disease. ( 29507995 )
2018
17
Gene expression analysis of porcine whole blood cells infected with foot-and-mouth disease virus using high-throughput sequencing technology. ( 29979724 )
2018
18
Modifications to the foot-and-mouth disease virus 2A peptide; influence on polyprotein processing and virus replication. ( 29386286 )
2018
19
Single-cell analysis of the impact of host-cell heterogeneity on infection with foot and mouth disease virus. ( 29444939 )
2018
20
Foot-and-Mouth Disease Virus Counteracts on Internal Ribosome Entry Site Suppression by G3BP1 and Inhibits G3BP1-Mediated Stress Granule Assembly <i>via</i> Post-Translational Mechanisms. ( 29887867 )
2018
21
Molecular epidemiology, evolution and phylogeny of foot-and-mouth disease virus. ( 29412184 )
2018
22
An improved, rapid competitive ELISA using a novel conserved 3B epitope for the detection of serum antibodies to foot-and-mouth disease virus. ( 29916768 )
2018
23
Identification of two novel foot-and-mouth disease virus cytotoxic T lymphocyte epitopes that can bind six SLA-I proteins. ( 29432828 )
2018
24
Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam. ( 29553326 )
2018
25
Different responses of weather factors on hand, foot and mouth disease in three different climate areas of Gansu, China. ( 29310596 )
2018
26
Complete Genome Sequences of Five Foot-and-Mouth Disease Viruses of Serotype A Isolated from Cattle in Nigeria between 2013 and 2015. ( 29449384 )
2018
27
The dynamics of the hand, foot and mouth disease epidemic from 2008 to 2016 in Zhenjiang city, China. ( 29634358 )
2018
28
Development of a chemiluminescence immunoassay using recombinant non-structural epitope-based proteins to accurately differentiate foot-and-mouth disease virus-infected and vaccinated bovines. ( 29341485 )
2018
29
An improved reverse transcription loop-mediated isothermal amplification assay for sensitive and specific detection of serotype O foot-and-mouth disease virus. ( 29964077 )
2018
30
Epidemiological Characteristics and Spatial-Temporal Distribution of Hand, Foot, and Mouth Disease in Chongqing, China, 2009-2016. ( 29401726 )
2018
31
Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine. ( 29559626 )
2018
32
Rapid detection of hand, foot and mouth disease enterovirus genotypes by multiplex PCR. ( 29758237 )
2018
33
Development and validation of a foot-and-mouth disease virus SAT serotype-specific 3ABC assay to differentiate infected from vaccinated animals. ( 29428400 )
2018
34
Hand, Foot and Mouth Disease and Echovirus 3: A Comment to HA,gsberg &amp;amp; Bygum. ( 29651498 )
2018
35
Correlation analysis on serum inflammatory cytokine level and neurogenic pulmonary edema for children with severe hand-foot-mouth disease. ( 29724230 )
2018
36
An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. ( 29175128 )
2018
37
Overview of foot-and-mouth disease awareness among farmers and veterinarians in France. ( 29907659 )
2018
38
Gianotti-Crosti syndrome and atypical hand-foot-mouth disease: two distinct entities or two manifestation of the same infection? ( 29963801 )
2018
39
Quantifying the influence of temperature on hand, foot and mouth disease incidence in Wuhan, Central China. ( 29386630 )
2018
40
Innate immune sensor LGP2 is cleaved by the Leader protease of foot-and-mouth disease virus. ( 29958302 )
2018
41
Stakeholder perceptions of foot-and-mouth disease control in South Africa. ( 29891144 )
2018
42
Correction to: Correlation analysis on serum inflammatory cytokine level and neurogenic pulmonary edema for children with severe hand-foot-mouth disease. ( 29907161 )
2018
43
Full-Genome Sequence of an Enterovirus 71 Strain Isolated from a Throat Swab from a Child with Severe Hand-Foot-and-Mouth Disease in Changzhou, China, in 2017. ( 29371346 )
2018
44
Hand-foot-mouth disease and use of steroids, intravenous immunoglobulin, and traditional Chinese herbs in a tertiary hospital in Shantou, China. ( 29925360 )
2018
45
Genetic stability of foot-and-mouth disease virus during long-term infections in natural hosts. ( 29390015 )
2018
46
Severity and burden of hand, foot and mouth disease in Asia: a modelling study. ( 29564154 )
2018
47
Evaluation of environmental sampling as a low technology method for surveillance of Foot-and-mouth disease virus in an endemic area. ( 29959244 )
2018
48
Hand, Foot and Mouth Disease in the Andaman Islands, India. ( 29845955 )
2018
49
Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. ( 29411190 )
2018
50
Parental perspectives on hand, foot, and mouth disease among children in Hong Kong: a longitudinal study. ( 29386079 )
2018

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 ATG5 CRP EIF4G1 HMGB1 IFNA1 IFNG
2
Show member pathways
13.36 EIF4G1 IFNA1 IFNG IL10 IL17F IL6
3
Show member pathways
13.03 BECN1 IFNA1 IL6 IRF3 ITGAV STAT1
4
Show member pathways
12.89 EIF4G1 IFNA1 IFNG IL10 IL6 STAT1
5 12.83 IFNA1 IFNG IL6 ITGAV NOTCH1 STAT1
6
Show member pathways
12.83 ATG5 IFNA1 IFNG IL10 IL6 IRF3
7
Show member pathways
12.77 IFNA1 IFNG IL6 IRF3 STAT1 TLR3
8
Show member pathways
12.75 IFNA1 IL6 IRF3 ITGAV NOTCH1 STAT1
9
Show member pathways
12.62 IRF3 ITGAV TLR3 TLR4 VTN
10
Show member pathways